Heterologous booster vaccination with CoronaVac following prime vaccination with mRNA vaccine
Abstract Objective Despite the high vaccine efficacy of mRNA COVID‐19 vaccines, there are individuals who developed excessive reactogenic and/or allergic responses after the first mRNA dose and were considered ineligible for further mRNA doses. CoronaVac, an inactivated SARS‐CoV‐2 vaccine, is recomm...
保存先:
| 主要な著者: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Wiley
2022-01-01
|
| シリーズ: | Clinical & Translational Immunology |
| 主題: | |
| オンライン・アクセス: | https://doi.org/10.1002/cti2.1403 |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|
